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Summary Background: Insulin-resistant hyperglycae-
mia may occasionally complicate the clinical course of
organic acidaemias. Study Design: Clinical observa-
tion. Results: Two term infants, one suffering from
acute early-onset methylmalonic acidaemia, the other
suffering from acute early-onset propionic acidaemia,
presented acutely with dehydration, ketoacidosis, and
hyperammonaemia. Urinary organic acid, plasma
amino acids, and blood and plasma acylcarnitine
analysis allowed the diagnosis of methylmalonic and
propionic acidaemias. The detection of the novel
c.481G>A (p.Gly161Arg) and the known c.655A>T
(p.Asn219Tyr) MUT gene mutations identified the
first patient as affected by methylmalonic acidaemia
mut type. The high increase of propionylcarnitine after
carnitine administration in both patients suggested
a greatly elevated metabolic intoxication. Both
newborns showed insulin-resistant hyperglycaemia.
Patient 1 died, but patient 2, after a strong reduction
of glucose administration, survived. To our knowledge,
this is the only patient with this complication who
survived. Conclusion: Insulin-resistant hyperglycaemia
complicating neonatal onset of methylmalonic and
propionic acidaemias is probably a marker of a serious
disease. One patient with this complication survived
after a strong reduction of glucose administration.
Even if this is probably only a partial intervention, we
hypothesize that in this situation a reduction of glucose
administration can reduce almost the risk of persistent
hyperglycaemia. Further studies are required to con-
firm our hypothesis.
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Introduction
Propionic and methylmalonic acidaemias (PA and
MMA) in their severe neonatal-onset forms are
disorders with a high mortality and poor outcomes
(Deodato et al 2006; Hori et al 2005). PA (OMIM
606054) is caused by a deficiency of propionyl-CoA
carboxylase (PCC), a mitochondrial biotin-dependent
enzyme that catalyzes the first step in the catabolism of
propionyl-CoA. Both PCCA and PCCB genes, encod-
ing the alpha and beta subunits of PCC, have been
correlated with PA. Isolated MMA is mostly caused by
a deficiency of methylmalonyl-CoA mutase (MCM)
(OMIM 251000; MMA mut type), a vitamin B12-
dependent enzyme that converts 1-methylmalonyl-
CoA to succinyl-CoA. Mutations in the MUT gene,
encoding MCM, may be responsible for partial or
complete enzyme deficiency (mutj and mut0 biochem-
ical phenotype, respectively). Both PA and mut MMA
are characterized by a greatly increased concentration,
respectively, of propionyl-CoA and methylmalonyl-
CoA, resulting, respectively, in an increased amount of
propionic and methylmalonic acids in blood and urine
(Fenton et al 2001).
Usually, the first signs of these diseases are feeding
refusal, drowsiness, dehydration, hypotonia of the
trunk and hypertonia of upper and lower limbs. Later,
seizures, lethargy, cerebral oedema and finally coma
may appear. Laboratory investigations show usually
ketosis or ketoacidosis, hyperammonaemia, moderate
hypocalcaemia, neutropenia, thrombocytopenia,
hyperlactacidaemia and hypoglycaemia (Fenton et al
2001). The diagnosis is usually confirmed by blood or
plasma acylcarnitine profile, urinary organic acid
analysis, enzyme assay, or molecular analysis.
Emergency treatment includes rehydration, stimula-
tion of diuresis, correction of acidosis, a hypercaloric
nutritional intake of glucose to prevent further protein
and fat catabolism, specific vitamins, and oral or intrave-
nous carnitine to assist the excretion of organic metabo-
lites. Treatment with sodium benzoate and arginine
hydrochloride is suggested if ammonium levels are high.
An unusual complication of MMA and PA is a
severe insulin-resistant hyperglycaemia (Boeckx and
Hicks 1982; Ciani et al 2000; Lehnert et al 1980). Few
cases are described at neonatal and paediatric ages,
associated with high mortality (Boeckx and Hicks
1982; Ciani et al 2000; Lehnert et al 1980). We describe
two patients affected by MMA and PA respectively
with severe neonatal onset and insulin-resistant hyper-
glycaemia. To our knowledge, the patient with PA
described here is the only patient with this complica-
tion who survived.
Material and methods
GC-MS and MS/MS analysis
Urinary organic acids were measured with an Agilent
6890N gas chromatograph coupled to a 5973 mass
spectrometry system (Agilent Technologies, Palo Alto,
CA, USA). Acylcarnitine analysis was carried out on
an API 4000 spectrometer (Applied Biosystems/MDS
Sciex, Foster City, CA, USA) according to the
conventional method as previously reported (Chace
et al 1993; Millington et al 1990) with some modifica-
tions (la Marca et al 2003). Data were acquired with
Analyst software and analysed automatically using
ChemoView (Applied Biosystems).
Molecular analysis
Molecular analysis was performed after the parents_
informed consent had been obtained. Unfortunately,
parents of patient 2 affected by PA denied informed
consent for mutation detection in PCCA and PCCB
genes. Genomic DNA of patient 1 and his parents was
isolated from whole blood using QIAamp DNA kit
(Quiagen, Hilden, Germany). Specific primer sets
were designed to amplify all MUT exons and intron-
exon junctions. PCR products were checked on a 1.5%
agarose gel and purified using the QIAquick gel
extraction kit (Quiagen, Hilden, Germany). Mutation
detection was performed by nucleotide sequencing on
an ABI PRISM 310 genetic analyser using BigDye
terminator chemicals (Applied Biosystems).
Consent to publication was obtained from the
parents of both patients reported and from the
Institutional Review Board.
Clinical reports
Patient 1
Patient 1, male, was born to non-consanguineous
parents after a normal pregnancy and delivery. Birth
weight was 3240 g; gestational age was 41+2 weeks;
Apgar index was 9–9 at 1 and 5 min, respectively. He
had a physiological course for the first 24 h of life.
Weight loss was 420 g in 48 h and lazy feeding was
noted. At the third day of live he showed tachypnoea
and general conditions were worsening, and the
newborn was transferred to our neonatal intensive
care unit (NICU).
Intravenous glucose (7 mg/kg per min) and bicar-
bonate infusion were started to correct the metabolic
acidosis (pH 7.102; base excess b24.3 mmol/L; HCO3
b
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7.9 mmol/L). Blood spot acylcarnitine profile
revealed increased propionylcarnitine (C3) concen-
trations of 12.2 Hmol/L (normal value <3.3 Hmol/L)
and methylmalonylcarnitine (C4DC) concentrations
of 0.54 Hmol/L, at the upper limit of the normal
range (<0.54 Hmol/L), plasma amino acids showed
glycine concentration of 751 Hmol/L (normal 158–
337 Hmol/L). Coagulation profile was normal. Urine
organic acid analysis showed an increased excretion
of lactic acid (306 Hmol/mmol creatinine, normal
<25), methylmalonic acid (2919 Hmol/mmol creati-
nine, normal <2) and methylcitric acid (30 Hmol/mmol
creatinine, normal <2). Plasma homocysteine was
normal. The clinical and laboratory investigations
suggested the diagnosis of methylmalonic acidaemia
type mut. The diagnosis was then confirmed by
molecular analysis of the MUT gene. The proband
resulted a compound heterozygote for the known
c.655A>T (p.Asn219Tyr) and the novel c.481G>A
(p.Gly161Arg) genetic lesions, both localized in exon
3. The two mutations were inherited from the
patient_s father and mother, respectively. The novel
c.481G>A, leading to the p.Gly161Arg amino acid
substitution, was not found in 120 sequenced alleles
of unrelated control subjects.
Treatment with N-carbamylglutamate (150 mg/kg
per day) and arginine hydrochloride (360 mg/kg in 2 h)
was started to correct hyperammonaemia (559 Hg/dl)
and L-carnitine (200 mg three times daily) was added.
After carnitine administration, C3 increased to 78.6
and C4DC to 1.19 Hmol/L. Repeated blood gas analysis
showed a persistent severe metabolic acidosis despite
the treatment with bicarbonate. After 12 hours of
treatment, ammonium decreased to 188 Hg/dl. At day
four, clinical conditions worsened, the infant was
intubated and mechanically ventilated, and sodium
benzoate (250 mg/kg per day) was added because the
ammonium level increased further (214 Hg/dl). Intra-
venous glucose infusion was increased until 12 mg/kg
per min was reached and 2 g/kg of intravenous lipids
were added, to increase the caloric intake to more than
356 kJ/kg (85 kcal/kg) and to promote anabolism.
However, early severe hyperglycaemia was observed;
insulin therapy was unsuccessfully started and progres-
sively increased to a dose of 1 U/kg per h. Intravenous
glucose infusion was therefore reduced quickly to
7 mg/kg per min. Insulin therapy was further increased
until 4.8 U/kg per h, but glucose plasma concentrations
increased until 48.3 mmol/L even if glucose infusion
was further reduced to 5 mg/kg per min and an oral
feeding giving a glucose contribution of 4.5 mg/kg per
min was added (Fig. 1). At the same time general
conditions worsened, a dramatic increase of lactate
concentration was noted, blood acylcarnitines (C3
295 Hmol/L, C4DC 1.26 Hmol/L) and urine organic
acids profiles (lactic 4398 Hmol/mmol creatinine,
methylmalonic 5296 Hmol/mmol creatinine) demon-
strated the catastrophic metabolic decompensation,
and the following day the infant died after a pulmo-
nary haemorrhage.
Patient 2
Patient 2, female, was born to non-consanguineous
parents after a normal pregnancy and delivery. Birth
weight was 3080 g; gestational age was 38+4 weeks;
Apgar index was 9–10. From the second day of life, lazy
feeding and poor reactivity were noted. Laboratory
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Fig. 1 Metabolic profile (glucose and lactate plasma concentrations) during glucose and insulin administration in patient 1
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investigations revealed metabolic acidosis (pH 7.08,
HCO3
b 5.3 mmol/L, BE b21.3 mmol/L) and hyper-
ammonaemia (770 Hg/dl). Oral feeding was stopped
and intravenous glucose infusion (8 mg/kg per min),
treatment with sodium benzoate (250 mg/kg) and
arginine hydrochloride (360 mg/kg) in 2 h were started,
and the newborn was transferred to our NICU at third
day of life.
On admission the infant was in fairly good general
condition, spontaneously breathing, but generalized
seizures with hypertonic upper and lower limbs
required treatment with phenobarbital. Cerebral ultra-
sound showed signs of cerebral oedema. Intravenous
lipids (2 g/kg) were added to the glucose infusion in
order to increase the caloric intake to around 293 kJ/kg
(70 kcal/kg), and to promote a faster metabolic detox-
ification oralN-carbamylglutamate (150 mg/kg per day)
was added. Blood acylcarnitines (C3 6.18 Hmol/L), and
urine organic acids profiles (lactic 285 Hmol/mmol
creatinine, 3-hydroxy-propionic 553 Hmol/mmol creat-
inine, methylcitrate 36 Hmol/mmol creatinine, tiglyl-
glycine 25 Hmol/mmol creatinine) suggested the
diagnosis of propionic acidaemia. L-Carnitine (100 mg/
kg per day), sodium bicarbonate and sodium phenyl-
butyrate (250 mg/kg per day) were added. Warming
was stopped and the neonate went spontaneously into
hypothermia reaching 34.5-C. Plasma ammonium con-
centrations decreased to 254 Hg/dl within 6 h and
normalized after 12 h. At this point the infant was
re-warmed to 37-C. Twenty-four hours after carnitine
administration, C3 increased to 80.1 Hmol/L. Because
of the severe increase of glucose plasma concentra-
tions, insulin therapy was unsuccessfully started and
rapidly increased to a dose of 1.2 U/kg/h (Fig. 2).
Simultaneously, serious hyponatraemia appeared. Liver
function (coagulation profile, total protein concentra-
tion) was normal. After 24 h of hospitalization, clinical
conditions worsened, and the infant was intubated for
recurrent apnoea and pulmonary haemorrhage. Plasma
concentrations of 3-hydroxybutyrate and acetoacetate
at 36 h of hospitalization were 839 and 844 Hmol/L,
respectively.
On the basis of the earlier experience at hour 40 of
hospitalization we significantly reduced and then
stopped the intravenous glucose infusion, increasing
the oral glucose administration. Lactate concentra-
tions were only mildly increased. Glucose concen-
trations decreased and normalized in 6 hours; insulin
was rapidly stopped and an improvement of clinical
conditions was observed. In the following days,
thrombocytopenia and leukopenia were noted. N-
Carbamylglutamate, sodium benzoate and arginine
hydrochloride were progressively reduced and sus-
pended on the 10th day of life.
Cerebral magnetic resonance imaging (MRI) at
19 days of life showed wide alteration of signal in the
white substance with low differentiation between it
and the cerebral cortex reduced in thickness. A video-
electroencephalogram (EEG) at 12 days of life showed
the presence of multifocal paroxystic anomalies. The
girl showed a slowly but continuously improving
neurological case history. She began to be bottle-fed
and she was discharged at 29 days of life. At 2 months
of life a cerebral MRI showed a signal reduction in the
white matter and a diffuse cerebral hypotrophy on T2-
weighed images. The child was in good general
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Fig. 2 Metabolic profile (glucose and lactate plasma concentrations) during glucose and insulin administration in patient 2
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condition and responsive, but she presented axial
hypotonia with head control only for short time.
Discussion
Patients with early-onset MMA and PA often demon-
strate abnormal carbohydrate homeostasis. In MMA,
hypoglycaemia occurs in about 40% of affected patients
(Worthen et al 1994). Many mechanisms were proposed
to explain this phenomenon. The intracellular accumu-
lation of CoA as methylmalonyl-CoA (MMCoA) could
produce insufficiency of this coenzyme and impair
carbohydrate metabolism (Oberholzer et al 1967).
Other studies suggested that the excess of MMCoA
inhibits the pyruvate carboxylase (PC) activity, which
prevents gluconeogenesis and provokes hypoglycaemia
(Scrutton et al 1965). Moreover MMCoA was observed
to inhibit the synthesis of malate, a key step in
gluconeogenesis and the main transmitochondrial shut-
tle of reducing equivalents (Fig. 3) (Halperin et al
1971). In patients with PA the accumulation of pro-
pionyl-CoA (PCoA) inhibits mainly pyruvate dehydro-
genase (PDH), resulting in a fall of acetyl-CoA levels.
This reduces PC activity due to a lowered allosteric
activation by acetyl-CoA and accounts for the observed
inhibition of gluconeogenesis and consequent hypogly-
caemia (Martin-Requero et al 1983).
Treatment of acute neonatal onset includes a high
intake of glucose to prevent protein and fat catabo-
lism. If hyperglycaemia appears, insulin infusion can
theoretically be very useful because, as a potent
anabolic hormone, it may suppress catabolism and
promote protein and lipid synthesis, facilitating the
uptake of harmful amino acid precursors (Wendel et al
2006). However, insulin-resistant hyperglycaemia in
such patients has been occasionally reported (Boeckx
and Hicks 1982; Ciani et al 2000; Lehnert et al 1980).
Boeckx and colleagues (Boeckx and Hicks 1982)
described a newborn affected by MMA complicated
by a severe insulin-resistant hyperglycaemia, hypocal-
caemia, metabolic acidosis. The patient died on the 8th
day of life, and the authors hypothesized that another
biochemical defect was responsible for the hyper-
glycaemia, such as an insulin-receptor defect. Another
case of lethal PA associated with severe hyperglycae-
mia was described by Lehnert and colleagues (1980).
Ciani and colleagues (2000) described an apparently
previously healthy 12-year-old girl admitted to the
intensive care unit with progressive loss of conscious-
ness associated with ketoacidosis, hyperammonaemia,
hyperglycaemia and lactic acidosis, and a consequent
diagnosis of insulin-dependent diabetes mellitus. This
patient died three days after the hospitalization, but
the post-mortem examination brought a diagnosis of
MMA. Her older brother died at the age of 15 years
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with the diagnosis of Reye syndrome complicated by
hyperglycaemia.
Until now, all reported patients with organic acid-
aemias associated with severe insulin-resistant hyper-
glycaemia have died within a few days, suggesting that
hyperglycaemia could be a marker of more serious
metabolic decompensation.
Here, we report two clinical cases, one of MMA and
the other of PA, both with acute neonatal onset
associated with insulin-resistant hyperglycaemia. Both
the newborns showed a severe form of these diseases,
as confirmed by the clinical course, by elevated values
of plasma acylcarnitines after carnitine administration,
and by the urinary organic acids analysis and fromMUT
gene mutations identified in the newborn with MMA,
described as patient 1. This patient was compound
heterozygous for the c.655A>T (p.Asn219Tyr) and
c.481G>A (p.Gly161Arg) mutations, both localized in
the MCM N-terminal barrel domain containing the
active site. It is known that more than 75% of mut0
mutations affect the barrel domain, while the mutb
mutations affect residues located in the C-terminal
cofactor-binding domain (Acquaviva et al 2005). The
p.Asn219Tyr is reported as a frequent mutation among
caucasian mut0 MMA patients (Acquaviva et al 2001).
The Gly161Arg affects a highly conserved residue of
the MCM barrel domain and the substitution of a
glycine with an arginine is predicted to cause a
hydrophobicity change at buried site, resulting in
a destabilization of the barrel domain (PolyPhen server:
http://www.bork.embl-heidelberg.de/PolyPhen; accessed
January 2009). The absence of the c.481G>A (p.
Gly161Arg) substitution in 120 control alleles, the high
phylogenetic conservation of the Gly161 amino acid
and the bioinformatic data strongly suggest that the
c.481G>A (p.Gly161Arg) is a disease-causing mutation.
However, the formal proof of pathogenetic mechanism
for this mutation will require further biochemical
investigations, such as overexpression and kinetic
analysis of the mutant enzyme. Although biochemical
studies on fibroblast from patient 1 were not carried
out, the severe clinical picture and the detected MUT
gene mutations involving highly conserved residues of
the barrel domain lead us to hypothesize that this
patient is affected by the mut0 phenotype.
PA and MMA represent different diseases that affect
different metabolic pathways.Moreover, thesemetabolic
defects affect enzymes that play a key role in different
organs (PC in liver and PDH in muscle), with different
effects on glucosemetabolism. This probably explains the
different outcomes of the two infants.
Patient 1 developed a persistent lactic acidosis
concomitant with progressive hyperglycaemia. These
complications can be explained by the intramitochon-
drial storage of MMCoA, which inhibits PC, and the
synthesis of malate. This produces an inhibition of the
malate—aspartate shuttle, the main system for transfer
of reducing equivalents into mitochondria (Bremer
and Davis 1975). The shuttle inhibition produces an
elevation in the cytoplasmic redox potential and
NADH/NAD+ ratio and consequently an elevation of
the concentration ratios of lactate/pyruvate. This
means that intramitochondrial pyruvate utilization is
reduced and that cytoplasmic pyruvate is converted to
lactate (Fig. 3) (Barron et al 1998). The glucose
concentrations in patient 1 did not diminish despite
an attempt (probably belated) to reduce the glucose
administration.
Also the newborn with PA described as patient 2
showed insulin-resistant hyperglycaemia. Glucose con-
centrations were less high but her clinical history was
less dramatic than patient 1 and she survived. To our
knowledge, this is the only newborn with this compli-
cation to survive. Indeed, lactic acidosis did not occur,
probably because PCoA does not inhibit malate
synthesis. This means that the cytoplasmic redox
potential and NADH/NAD ratio were normal and
therefore pyruvate was not converted to lactate. The
hyperglycaemia of this newborn resolved and clinical
conditions improved rapidly only with a strong reduc-
tion of intravenous glucose administration, replaced
with a progressive increase of oral glucose. Oral
glucose was better tolerated than intravenous glucose,
probably because oral glucose enters the liver via an
insulin-independent mechanism. Besides, the liver of
patients with PA is able to oxidize glucose, shifting
glucose via PC to oxaloacetate.
We cannot claim that a strong reduction of glucose
infusion in patient 1 would have avoided his death, as
happened to the patient 2. In fact the death of patient
1 was due predominantly to lactic acidosis secondary
to the failure of PC activity. However, it can be
assumed that also in patient 1, a drastic reduction of
glucose administration would probably have allowed
to control hyperglycaemia and to reduce lactate
concentrations.
This clinical evolution enables us to comprehend
that hyperglycaemia in this case was not due to an
underlying disease associated with PA (as supposed in
other patients) (Boeckx and Hicks 1982), but rather to
a transitory and reversible intolerance to high glucose
concentrations. For this reason, we suggest that hyper-
glycaemia could be a seriousness marker.
The clinical course of patient 2 was characterized
by serious hyponatraemia. Hypertonicity secondary
to hyperglycaemia was probably the major cause of
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hyponatraemia. In fact hyponatraemia is relatively
common in diabetic children (Walters and Hughes
1984), because hyperglycaemia promotes both an
osmotic diuresis and an osmotic shift of water from
within the cells to the extracellular fluid. This in turn
decreases the plasma sodium concentration by dilu-
tion. Hyponatraemia can promote the development
of cerebral oedema (Hale et al 1997) and it therefore
may have played a role in the clinical neurological
outcome. We are not able to explain the develop-
ment of pulmonary haemorrhage in reported
patients. Coagulation profile and liver function
allowed us to exclude a relationship with liver failure
or disseminated intravascular coagulation. However,
in infants suffering from congenital organic acid-
aemias, pulmonary congestion has sometimes been
observed (Ozand et al 1994).
Regarding the mechanism of this hyperglycaemia, in
our patients we were not able to measure the glucose
production and therefore we are not able to specify
whether hyperglycaemia was due to an inappropriate
hepatic endogenous glucose output or to a reduced
muscular or adipose glucose uptake, even if this option
appears more likely. Moreover, we must not overlook
that both newborns received intravenous lipid infusion.
It is well known that fatty acids induce insulin
resistance in muscle (Kruszynska et al 2002). It is
therefore possible that lipid infusion may have accen-
tuated the hyperglycaemia. The high levels of ketone
bodies were probably due more to the insulin resis-
tance than to the enzymatic defect.
In conclusion, this clinical observation, together with
literature data, prompts us to suspect that the occurrence
of insulin-resistant hyperglycaemia can identify
newborns at higher risk of death. The outcome of both
reported infants allows us to suggest, in newborns with
this complication, reduction of the glucose infusion,
which in patients with MMA could lead to lethal
hyperlactacidaemia. It is likely that even if we had
drastically reduced the intake of glucose in newborn
patient 1, this would not have prevented the infant_s
death. However, we hope to undertake further research
to assess whether a drastic reduction of glucose intake in
these patients might allow at least avoidance of compli-
cations secondary to a persistent hyperglycaemia.
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